Faget Quoted on FDA’s Decision to Stop Reviewing COVID-19 Lab Tests
October 7, 2020
BioCentury
Of Counsel Kyle Faget was quoted in a BioCentury article, “FDA to stop reviewing COVID-19 lab tests, raising concerns in Congress,” about the FDA’s announcement that it will no longer review emergency use authorization requests for laboratory developed tests to diagnose COVID-19.
The article cites an Aug. 24 blog post by Faget, who wrote that bringing an LDT to market without securing FDA premarket approval or clearance of, or an emergency use authorization (EUA), comes at a steep cost to clinical laboratories. “Public Health and Emergency Preparedness Act (PREP Act) protection is not available to clinical laboratories opting to use LDTs without FDA premarket review or authorization,” she wrote.
People
Related News
July 11, 2025
In the News
David Morris Featured for Arrival to Foley's Salt Lake City Office
Foley & Lardner LLP partner David Morris is highlighted across legal press for his recent arrival to the firm.
July 10, 2025
In the News
Ann Marie Uetz Comments on Automotive Supply Chain Approach to Evolving Tariff Environment
Foley & Lardner LLP partner Ann Marie Uetz shared perspective from the automotive supply chain amid the evolving trade environment in the Crain's Detroit article, "Ford, Stellantis tighten terms on suppliers as tariff costs add up."
July 7, 2025
In the News
Louis Lehot Assesses Deal Trends in Shifting Market
Foley & Lardner LLP partner Louis Lehot assessed dealmaking trends in the Law360 article, "PE Dealmakers Best-Suited To Cut Through M&A Challenges."